[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Diakos, C.I., Charles, K.A., McMillan, D.C. and Clarke, S.J. (2014) Cancer-Related Inflammation and Treatment Effectiveness. The Lancet Oncology, 15, e493-e503. https://doi.org/10.1016/S1470-2045(14)70263-3
|
[3]
|
Hoshimoto, S., Hishinuma, S., Shirakawa, H., Tomikawa, M., Ozawa, I. and Ogata, Y. (2019) Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma. Oncology, 96, 290-298. https://doi.org/10.1159/000499050
|
[4]
|
Kumamoto, Y., Kaizu, T., Tajima, H., Nishizawa, N., Ei, S., Igarashi, K. and Watanabe, M. (2018) Neutrophil-to- Lymphocyte Ratio as a Predictor of Postoperative Morbidity in Patients with Distal Cholangiocarcinoma. Molecular and Clinical Oncology, 9, 362-368. https://doi.org/10.3892/mco.2018.1698
|
[5]
|
Yang, R., Chang, Q., Meng, X., Gao, N. and Wang, W. (2018) Prog-nostic Value of Systemic Immune-Inflammation Index in Cancer: A Meta-Analysis. Journal of Cancer, 9, 3295-3302. https://doi.org/10.7150/jca.25691
|
[6]
|
Hu, B., Yang, X.R., Xu, Y., Sun, Y.F., Sun, C., Guo, W., Zhang, X., Wang, W.M., Qiu, S.J., Zhou, J. and Fan, J. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research: An Official Journal of the American Associ-ation for Cancer Research, 20, 6212- 6222. https://doi.org/10.1158/1078-0432.CCR-14-0442
|
[7]
|
Wilson, C.L., Jurk, D., Fullard, N., Banks, P., Page, A., Luli, S., Elsharkawy, A.M., Gieling, R.G., Chakraborty, J.B., Fox, C., Rich-ardson, C., Callaghan, K., Blair, G.E., Fox, N., Lagnado, A., Passos, J.F., Moore, A.J., Smith, G.R., Tiniakos, D.G., Mann, J. and Mann, D.A. (2015) NFκB1 Is a Suppressor of Neutrophil-Driven Hepatocellular Carcinoma. Nature Communications, 6, 6818. https://doi.org/10.1038/ncomms7818
|
[8]
|
Gupta, S.C., Hevia, D., Patchva, S., Park, B., Koh, W. and Aggarwal, B.B. (2012) Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Re-active Oxygen Species in Tumorigenesis, Prevention, and Therapy. Antioxidants & Redox Signaling, 16, 1295-1322. https://doi.org/10.1089/ars.2011.4414
|
[9]
|
Chen, H., Zhou, X.H., Li, J.R., Zheng, T.H., Yao, F.B., Gao, B. and Xue, T.C. (2021) Neutrophils: Driving Inflammation during the Development of Hepatocellular Carcinoma. Cancer Let-ters, 522, 22-31.
https://doi.org/10.1016/j.canlet.2021.09.011
|
[10]
|
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R. and Mantovani, A. (2020) Neutrophil Diversity and Plasticity in Tumour Progression and Therapy. Nature Reviews Cancer, 20, 485-503.
https://doi.org/10.1038/s41568-020-0281-y
|
[11]
|
Lin, S., Hu, S., Ran, Y. and Wu, F. (2021) Neutro-phil-to-Lymphocyte Ratio Predicts Prognosis of Patients with Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. Translational Cancer Research, 10, 1667-1678.
https://doi.org/10.21037/tcr-20-3237
|
[12]
|
Heras, P., Hatzopoulos, A., Kritikos, N. and Kritikos, K. (2010) Platelet Count and Tumor Progression in Gastric Cancer Patients. Scandinavian Journal of Gastroenterology, 45, 1005-1006.
https://doi.org/10.3109/00365521003797221
|
[13]
|
Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., He, Y., Liao, Q., Xiang, B., Zhou, M., Guo, C., Zeng, Z., Li, G., Li, X. and Xiong, W. (2020) The Role of Microenvironment in Tumor Angiogenesis. Journal of Experimental & Clinical Cancer Research: CR, 39, 204. https://doi.org/10.1186/s13046-020-01709-5
|
[14]
|
Anvari, S., Osei, E. and Maftoon, N. (2021) Interactions of Platelets with Circulating Tumor Cells Contribute to Cancer Metastasis. Scientific Reports, 11, Article No. 15477. https://doi.org/10.1038/s41598-021-94735-y
|
[15]
|
于潇, 武国兵, 张爱斌, 程晓龙, 刘敏, 胡泽楠, 陈兆峰. 血小板在肝细胞癌发生发展中的作用[J]. 临床肝胆病杂志, 2022(6): 1426-1430.
|
[16]
|
Ha, S.Y., Choi, S., Park, S., Kim, J.M., Choi, G.S., Joh, J.W. and Park, C.K. (2020) Prognostic Effect of Preoperative Neutrophil-Lymphocyte Ratio Is Related with Tumor Necrosis and Tumor-Infiltrating Lymphocytes in Hepatocellular Carcinoma. Virchows Archiv: An International Journal of Pathology, 477, 807-816.
https://doi.org/10.1007/s00428-020-02841-5
|
[17]
|
Spector, M.E., Bellile, E., Amlani, L., Zarins, K., Smith, J., Brenner, J.C., Rozek, L., Nguyen, A., Thomas, D., McHugh, J.B., Taylor, J.M.G., Wolf, G.T. and University of Michi-gan Head and Neck SPORE Program (2019) Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology—Head & Neck Surgery, 145, 1012-1019. https://doi.org/10.1001/jamaoto.2019.2427
|
[18]
|
Ocana, A., Nieto-Jiménez, C., Pandiella, A. and Templeton, A.J. (2017) Neutrophils in Cancer: Prognostic Role and Therapeutic Strategies. Molecular Cancer, 16, 137. https://doi.org/10.1186/s12943-017-0707-7
|
[19]
|
Wang, B., Huang, Y. and Lin, T. (2020) Prognostic Impact of El-evated Pre-Treatment Systemic Immune-Inflammation Index (SII) in Hepatocellular Carcinoma: A Meta-Analysis. Medi-cine, 99, e18571.
https://doi.org/10.1097/MD.0000000000018571
|
[20]
|
王明弘, 江斌, 王健, 万云燕, 童泽辉, 潘浩. 系统免疫炎症指数与肝细胞癌切除术后预后相关性分析[J]. 腹部外科, 2022(1): 31-36+46.
|
[21]
|
Fu, H., Zheng, J., Cai, J., Zeng, K., Yao, J., Chen, L., Li, H., Zhang, J., Zhang, Y., Zhao, H. and Yang, Y. (2018) Systemic Immune-Inflammation Index (SII) Is Useful to Predict Survival Outcomes in Patients after Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physi-ology, Biochemistry, and Pharmacology, 47, 293-301.
https://doi.org/10.1159/000489807
|
[22]
|
Iavarone, M., Cabibbo, G., Biolato, M., Della Corte, C., Maida, M., Bar-bara, M., Basso, M., Vavassori, S., Craxì, A., Grieco, A., Cammà, C. and Colombo, M. (2015) Predictors of Survival in Patients with Advanced Hepatocellular Carcinoma Who Permanently Discontinued Sorafenib. Hepatology (Baltimore, Md.), 62, 784-791.
https://doi.org/10.1002/hep.27729
|
[23]
|
Casadei Gardini, A., Scarpi, E., Faloppi, L., Scartozzi, M., Silvestris, N., Santini, D., de Stefano, G., Marisi, G., Negri, F.V., Foschi, F.G., Valgiusti, M., Ercolani, G. and Frassineti, G.L. (2016) Immune Inflammation Indicators and Implication for Immune Modulation Strategies in Advanced Hepatocellular Carci-noma Patients Receiving Sorafenib. Oncotarget, 7, 67142-67149. https://doi.org/10.18632/oncotarget.11565
|
[24]
|
Hong, Y.M., Yoon, K.T. and Cho, M. (2021) Systemic Im-mune-Inflammation Index Predicts Prognosis of Sequential Therapy with Sorafenib and Regorafenib in Hepatocellular Carcinoma. BMC Cancer, 21, 569.
https://doi.org/10.1186/s12885-021-08124-9
|
[25]
|
Ding, P., Guo, H., Sun, C., Yang, P., Kim, N.H., Tian, Y., Liu, Y., Liu, P., Li, Y. and Zhao, Q. (2022) Combined Systemic Immune-Inflammatory Index (SII) and Prognostic Nutrition-al Index (PNI) Predicts Chemotherapy Response and Prognosis in Locally Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy with PD-1 Antibody Sintilimab and XELOX: A Prospective Study. BMC Gastroenterology, 22, 121.
https://doi.org/10.1186/s12876-022-02199-9
|
[26]
|
Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A.A., Tenti, E., Vespignani, R., Frassineti, G.L., Amadori, D. and De Giorgi, U. (2016) Inflammatory Indexes as Predictors of Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. Oncotarget, 7, 33210-33219. https://doi.org/10.18632/oncotarget.8901
|
[27]
|
Shrotriya, S., Walsh, D., Bennani-Baiti, N., Thomas, S. and Lorton, C. (2015) C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLOS ONE, 10, e0143080. https://doi.org/10.1371/journal.pone.0143080
|
[28]
|
Fairclough, E., Cairns, E., Hamilton, J. and Kelly, C. (2009) Evaluation of a Modified Early Warning System for Acute Medical Admissions and Comparison with C-Reactive Pro-tein/Albumin Ratio as a Predictor of Patient Outcome. Clinical Medicine (London, England), 9, 30-33. https://doi.org/10.7861/clinmedicine.9-1-30
|
[29]
|
Liu, X., Sun, X., Liu, J., Kong, P., Chen, S., Zhan, Y. and Xu, D. (2015) Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer. Translational Oncology, 8, 339-345.
https://doi.org/10.1016/j.tranon.2015.06.006
|
[30]
|
Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K., Fushiya, N., Koike, K., Nishino, H. and Matsushima, M. (2015) The C-Reactive Protein/Albumin Ratio, a Novel In-flammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 22, 803-810.
https://doi.org/10.1245/s10434-014-4048-0
|
[31]
|
Zhang, Y., Xiao, G. and Wang, R. (2019) Clinical Significance of Systemic Immune-Inflammation Index (SII) and C-Reactive Protein-to-Albumin Ratio (CAR) in Patients with Esophage-al Cancer: A Meta-Analysis. Cancer Management and Research, 11, 4185-4200. https://doi.org/10.2147/CMAR.S190006
|
[32]
|
Mirili, C., Yılmaz, A., Demirkan, S., Bilici, M. and Basol Tekin, S. (2019) Clinical Significance of Prognostic Nutritional Index (PNI) in Malignant Melanoma. International Journal of Clinical Oncology, 24, 1301-1310.
https://doi.org/10.1007/s10147-019-01461-7
|
[33]
|
Wang, D., Hu, X., Xiao, L., Long, G., Yao, L., Wang, Z. and Zhou, L. (2021) Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Pa-tients with HCC. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 25, 421-427.
https://doi.org/10.1007/s11605-019-04492-7
|